Mark A. Socinski

机构：Florida Hospital Cancer Institute, AdventHealth Tampa, AdventHealth · ORCID：0000-0003-2915-9325

发表论文 779 篇 · 总被引 37214 次 · h-index 84

代表论文

• Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity (2025 · Nature Communications · 被引 10)
• Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer (2026 · JAMA Oncology · 被引 6)
• Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations (2025 · Nature Communications · 被引 5)
• Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial (2026 · Nature Medicine · 被引 1)
• Artificial intelligence (AI) as a decision support tool for practicing oncologists. (2025 · JCO Oncology Practice · 被引 1)
• MA08.02 Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab (2025 · Journal of Thoracic Oncology · 被引 1)